Valneva SE (VALN) Interest & Investment Income (2021 - 2026)
Valneva SE (VALN) posted Interest & Investment Income of $615812.2 for Q1 2026, up 175.58% sequentially from -$814830.5 in Q4 2025, and up 14.57% YoY from $537512.9 in Q1 2025.
Analysis
Valneva SE (VALN) Interest & Investment Income (2021 - 2026) Analysis & Trends
Valneva SE has reported Interest & Investment Income for 6 years, with the latest figure at $615812.2 in Q1 2026.
- Quarterly Interest & Investment Income rose 14.57% year-over-year to $615812.2 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.0 million (down 28.25% YoY) and the FY2025 annual result came in at -$3.0 million, down 16.51% from the prior year.
- Interest & Investment Income improved to $615812.2 in Q1 2026 per VALN's latest filing, from -$814830.5 in the prior quarter.
- Over five years, Interest & Investment Income peaked at $627105.7 in Q2 2025 and troughed at -$3.5 million in Q3 2025.
- A 5-year average of -$208438.2 and a median of $239489.9 in 2023 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2022 and 2024: Interest & Investment Income surged 1891.79% in 2022, then slumped 1057.03% in 2024.
- Over 5 years, Interest & Investment Income stood at $205069.7 in 2022, then jumped by 154.99% to $522906.8 in 2023, then slumped by 324.79% to -$1.2 million in 2024, then soared by 30.68% to -$814830.5 in 2025, then surged by 175.58% to $615812.2 in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $615812.2, -$814830.5, and -$3.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.26 Bn | 131.41 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 57.83 Bn | 52.69 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 39.94 Bn | 34.84 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.19 Bn | 31.88 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Valneva SE | 588.63 Mn | 447.37 Mn | 1.86 Mn | 620,701.23 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 620,701.23 |
| Mar 31, 2026 | 615,812.21 |
| Dec 31, 2025 | -814,830.46 |
| Sep 30, 2025 | -3.47 Mn |
| Jun 30, 2025 | 627,105.67 |
| Mar 31, 2025 | 537,512.95 |
| Dec 31, 2024 | -1.18 Mn |
| Sep 30, 2024 | -2.29 Mn |
| Jun 30, 2024 | 561,058.43 |
| Mar 31, 2024 | 288,972.23 |
| Dec 31, 2023 | 522,906.80 |
| Sep 30, 2023 | 239,489.90 |
| Jun 30, 2023 | 273,320.02 |
| Mar 31, 2023 | 271,555.48 |
| Dec 31, 2022 | 205,069.72 |
| Sep 30, 2022 | 24,198.58 |
| Jun 30, 2022 | 23,475.25 |
| Mar 31, 2022 | 14,590.39 |
| Dec 31, 2021 | 10,295.74 |
| Sep 30, 2021 | 14,151.45 |